Aquatic Capital Management LLC Increases Holdings in Ultragenyx Pharmaceutical Inc. $RARE

Aquatic Capital Management LLC increased its position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 79.1% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 191,458 shares of the biopharmaceutical company’s stock after buying an additional 84,559 shares during the quarter. Aquatic Capital Management LLC owned 0.20% of Ultragenyx Pharmaceutical worth $5,759,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds also recently made changes to their positions in RARE. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its position in Ultragenyx Pharmaceutical by 14.8% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 232,360 shares of the biopharmaceutical company’s stock valued at $8,414,000 after buying an additional 29,984 shares during the period. Envestnet Asset Management Inc. grew its position in Ultragenyx Pharmaceutical by 6.0% during the 2nd quarter. Envestnet Asset Management Inc. now owns 29,956 shares of the biopharmaceutical company’s stock worth $1,089,000 after acquiring an additional 1,698 shares during the last quarter. Campbell & CO Investment Adviser LLC bought a new position in Ultragenyx Pharmaceutical during the 2nd quarter worth approximately $309,000. Geode Capital Management LLC increased its stake in Ultragenyx Pharmaceutical by 4.0% in the 2nd quarter. Geode Capital Management LLC now owns 1,712,931 shares of the biopharmaceutical company’s stock worth $62,291,000 after purchasing an additional 66,394 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey increased its stake in Ultragenyx Pharmaceutical by 7.6% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 34,592 shares of the biopharmaceutical company’s stock worth $1,258,000 after purchasing an additional 2,458 shares during the period. Institutional investors own 97.67% of the company’s stock.

Analyst Ratings Changes

A number of research firms have recently weighed in on RARE. Wedbush reissued a “neutral” rating and set a $25.00 price objective on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, February 17th. Bank of America decreased their target price on shares of Ultragenyx Pharmaceutical from $72.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, January 2nd. Canaccord Genuity Group lowered their price target on shares of Ultragenyx Pharmaceutical from $128.00 to $79.00 and set a “buy” rating for the company in a report on Wednesday, February 18th. JPMorgan Chase & Co. dropped their price target on shares of Ultragenyx Pharmaceutical from $120.00 to $74.00 and set an “overweight” rating for the company in a research report on Thursday, March 12th. Finally, Leerink Partners cut their price target on shares of Ultragenyx Pharmaceutical from $80.00 to $70.00 and set an “outperform” rating on the stock in a report on Tuesday, December 30th. Fifteen equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $62.69.

Ultragenyx Pharmaceutical Price Performance

RARE stock opened at $21.82 on Tuesday. Ultragenyx Pharmaceutical Inc. has a 1 year low of $18.41 and a 1 year high of $42.37. The firm has a 50-day moving average of $22.99 and a 200 day moving average of $28.75. The company has a market cap of $2.11 billion, a P/E ratio of -3.74 and a beta of 0.16.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Thursday, February 12th. The biopharmaceutical company reported ($1.29) earnings per share for the quarter, missing the consensus estimate of ($1.20) by ($0.09). Ultragenyx Pharmaceutical had a negative net margin of 85.54% and a negative return on equity of 1,024.42%. The firm had revenue of $207.28 million for the quarter, compared to the consensus estimate of $199.60 million. During the same period in the previous year, the firm posted ($1.39) earnings per share. The business’s revenue was up 25.5% compared to the same quarter last year. On average, equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -5.18 earnings per share for the current fiscal year.

Insider Activity at Ultragenyx Pharmaceutical

In related news, EVP Eric Crombez sold 7,029 shares of the company’s stock in a transaction on Monday, March 2nd. The stock was sold at an average price of $22.80, for a total value of $160,261.20. Following the sale, the executive vice president directly owned 76,301 shares of the company’s stock, valued at $1,739,662.80. This represents a 8.44% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CFO Howard Horn sold 1,635 shares of the stock in a transaction on Tuesday, March 3rd. The stock was sold at an average price of $22.40, for a total value of $36,624.00. Following the completion of the transaction, the chief financial officer owned 85,034 shares of the company’s stock, valued at approximately $1,904,761.60. This trade represents a 1.89% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold a total of 104,958 shares of company stock valued at $2,394,858 over the last ninety days. Insiders own 5.50% of the company’s stock.

Ultragenyx Pharmaceutical News Roundup

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Neutral Sentiment: One press release in the batch concerns a different “RARE” ticker (Tactical Resources Corp.) and is unrelated to Ultragenyx; it should be ignored for Ultragenyx-specific analysis. Tactical Resources Signs Agreement to Acquire the Sierra Blanca Quarry and Tailings Access for the Peak Rare Earth Project
• Negative Sentiment: Multiple national plaintiff firms (Rosen, Faruqi & Faruqi, Portnoy, Schall, Berger Montague, Bronstein Gewirtz & Grossman) have announced a class action or are soliciting lead‑plaintiff applicants for the same alleged class period (Aug 3, 2023–Dec 26, 2025), urging investors to act before the April 6, 2026 deadline — increasing the chance of coordinated litigation and potential settlement exposure. ROSEN, A TOP RANKED LAW FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – RARE
• Negative Sentiment: Faruqi & Faruqi issued a reminder about the April 6 lead‑plaintiff deadline and is investigating potential claims against Ultragenyx — another prominent firm publicizing the suit, which can increase publicity and plaintiff coordination. RARE INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Reminds Ultragenyx Pharmaceutical (RARE) Investors of Securities Class Action Deadline on April 6, 2026
• Negative Sentiment: Portnoy Law Firm announced a class action on behalf of Ultragenyx investors covering the same class period and deadline, adding to the number of active plaintiffs’ firms. Portnoy Law Firm Announces Class Action on Behalf of Ultragenyx Pharmaceutical, Inc. Investors
• Negative Sentiment: Schall Law Firm is soliciting lead‑plaintiff applicants for a securities fraud suit alleging violations of Sections 10(b) and 20(a); the legal claims are being actively marketed to investors which can amplify headline risk. RARE Investors Have Opportunity to Lead Ultragenyx Pharmaceutical Inc. Securities Fraud Lawsuit with the Schall Law Firm
• Negative Sentiment: Berger Montague published a securities-fraud notice about a filed class action covering the same dates and the April 6 deadline, increasing the number of firms involved. ULTRAGENYX PHARMACEUTICAL INC. SECURITIES FRAUD NOTICE: Berger Montague Informs Ultragenyx Pharmaceutical Inc. (RARE) Investors of a Securities Fraud Lawsuit
• Negative Sentiment: Bronstein, Gewirtz & Grossman also alerted investors to a class action alleging investor harm and the same April 6 deadline — another sign of broad plaintiff interest. Bronstein, Gewirtz & Grossman LLC Urges Ultragenyx Pharmaceutical Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.